Alligator presents promising 24-month data at ESMO GI 2025
2 juli, 09:50
2 juli, 09:50
Alligator Bioscience announced that new data from its ongoing phase Ib/II OPTIMIZE-1 trial will be presented at the ESMO Gastrointestinal Cancers Congress 2025, taking place in Barcelona on 2–5 July.
Read the article at biostock. se:
https://biostock.se/en/2025/07/alligator-presents-promising-24-month-data-at-esmo-gi-2025/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
2 juli, 09:50
Alligator Bioscience announced that new data from its ongoing phase Ib/II OPTIMIZE-1 trial will be presented at the ESMO Gastrointestinal Cancers Congress 2025, taking place in Barcelona on 2–5 July.
Read the article at biostock. se:
https://biostock.se/en/2025/07/alligator-presents-promising-24-month-data-at-esmo-gi-2025/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
Börsen idag
Börsen idag
Börsen idag
Börsen idag
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 512,53